<DOC>
	<DOCNO>NCT02865720</DOCNO>
	<brief_summary>The purpose study determine investigational treatment safe well tolerate administer intravenous ( IV ) infusion Japanese subject HAE .</brief_summary>
	<brief_title>Study C1 Inhibitor ( Human ) Prevention Angioedema Attacks Treatment Breakthrough Attacks Japanese Subjects With Hereditary Angioedema ( HAE )</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>1 . Be Japanese descent , define born Japan Japanese parent Japanese maternal paternal grandparent . 2 . Be ≥2 year age . 3 . Meet follow minimum body weight criterion : Subjects 2 5 year age must weigh least 12.5 kg ; Subjects 6 year age must weigh least 25 kg . 4 . Have confirm diagnosis Type I Type II HAE . NOTE : Diagnosis may base historical data include family history , clinical symptom ( characteristic attack ) , documentation low level C1 INH protein and/or C1 INH activity . 5 . Have history least one angioedema attack per month ( average ) 3 consecutive month immediately enrollment . 6 . Agree adhere protocoldefined schedule assessment procedure . 7 . Agree avoid his/her known angioedema attack trigger study best his/her ability . 8 . If female reproductive age , postmenopausal ( ≥12 month follow cessation menstruation ) , surgically sterile , follow acceptable method birth control ( agree continue use 1 month last dose study drug ) : Nonhormonal method ( eg , abstinence , barrier control ) least 1 complete menstrual cycle Screening Visit . Stable dos estrogen and/or progestin contain product least 2 month Screening Visit . 9 . If male reproductive age , surgically sterile agree follow acceptable method birth control ( eg , abstinence , barrier control ) Screening Visit 2 month last dose study drug . 10 . If adult , informed nature study provide write informed consent studyspecific procedure perform . OR If child minor ( &lt; 20 year age ) , parent/legal guardian inform nature study provide write informed consent ( ie , permission ) child participate study studyspecific procedure perform . Assent obtain child ≥14 year age . 1 . Have history hypercoagulability ( abnormal blood clotting ) . 2 . Have diagnosis acquire angioedema know C1 INH antibody . 3 . Have history allergic reaction C1 INH product , include CINRYZE ( component CINRYZE ) blood product . 4 . Have receive C1 INH therapy blood product within 3 day first dose study drug . 5 . Have sign symptom angioedema attack within 2 day first dose study drug . 6 . Have change ( start , stop , change dose ) androgen therapy ( eg , danazol , oxandrolone , stanozolol , testosterone ) , tranexamic acid , epsilonaminocaproic acid ( EACA ) , antifibrinolytics within 14 day first dose study drug . 7 . If female , start take change dose hormonal contraceptive regimen hormone replacement therapy ( eg , estrogen/progestin containing product ) within 2 month first dose study drug . 8 . Be pregnant breastfeeding . 9 . Have receive investigational drug require prevention treatment angioedema attack within 30 day first dose study drug . 10 . Have , determine Investigator and/or Sponsor 's Medical Monitor , surgical medical condition could interfere administration study drug interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>